CrossBridge Bio Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired CrossBridge Bio, a medical devices business in Texas, for up to $300 million. CrossBridge Bio is an innovative healthcare company backed by CE-Ventures, with an initial $10 million financing round in 2024 that supported its biotechnology development. Eli Lilly acquisitions in medical devices acquisition expand its healthcare M&A footprint in TX acquisitions by adding CrossBridge Bio’s technology and product pipeline. The CrossBridge Bio acquisition is structured as an add on acquisition and strategic acquisition under CE-Ventures’ corporate venture capital platform, with deal terms reported as up to $300 million and an announced status.